News

March 24, 2023

CancerVax CEO Ryan Davies Speaks with University of Utah Chemistry Professor about the Future of Therapeutic Research

Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX CEO Ryan Davies to discuss the future of novel therapeutics and how the industry can encourage young scientists to enter the field.

March 22, 2023

Leading Diabetes Researcher Speaks on his Groundbreaking ‘Edmonton Protocol’ with CancerVAX CEO Ryan Davies

Dr. Jonathan Lakey, Professor in University of California – Irvine’s Surgery and Biomedical Engineering departments, spoke with CancerVAX CEO Ryan Davies on his accomplishments in scientific research and their impact on the world

March 20, 2023

CancerVAX CEO Ryan Davies Sits Down with Oncology Research Leader

Dr. David Bearss, an oncology researcher and biotech start-up founder, spoke with CancerVAX CEO Ryan Davies on the future of oncology therapeutics

March 17, 2023

CancerVax Universal Cancer Vaccine Being Developed by UCLA

The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer vaccine (UCV) that will train the body to target and destroy cancer cells.

March 16, 2023

CancerVax Files Non-Provisional Patent for Universal Cancer Vaccine

The Company’s patent application describes how it plans to leverage cutting-edge CRISPR and mRNA technologies to develop a breakthrough universal cancer vaccine (UCV)

August 31, 2022

CancerVAX Announces Research Program to Develop Its Second Immunotherapy Cancer Treatment

The Company has entered into a Sponsored Research Agreement with UCLA to develop a new cancer immunotherapy universal cancer vaccine.

October 6, 2021

CancerVAX Files Provisional Patent for a Universal Cancer Vaccine

The Company plans to leverage cutting-edge CRISPR and mRNA technologies in its quest to develop a breakthrough universal cancer vaccine (UCV).

October 1, 2021

Biotech Executive Joins CancerVAX

New CEO Ryan Davies will lead the Company’s development of its breakthrough immunotherapy treatment SANTA BARBARA, CA – October 1, 2021 – CancerVAX, Inc.

May 26, 2021

CancerVAX Announces Research Program

The Company has entered into an agreement with UCLA to develop an immunotherapy breakthrough targeted at treating Ewing sarcoma, a rare but deadly soft tissue and bone cancer that primarily affects children and young adults.

March 30, 2021

CancerVAX Closes Series A Funding Round

SANTA BARBARA, CA – March 30, 2021 – CancerVAX, Inc., a developer of immunotherapy cancer treatments that use the body’s immune system to fight cancer, today announced it has closed its $2 million series A funding round.

March 23, 2021

CancerVAX Launched

The Company was founded by experienced healthcare executive Lindsay Mann